The risks of neonatal convulsions and neonatal withdrawal syndrome seem to increase when a pregnant women uses selective serotonin reuptake inhibitors (SSRIs), with paroxetine being the worst offender, according to cases reported by 72 countries to the World Health Organization's Collaborating Centre for International Drug Monitoring in Uppsala, Sweden.
The risks of neonatal convulsions and neonatal withdrawal syndrome seem to increase when a pregnant women uses selective serotonin reuptake inhibitors (SSRIs), with paroxetine being the worst offender, according to cases reported by 72 countries to the World Health Organization's Collaborating Centre for International Drug Monitoring in Uppsala, Sweden.
Of 93 suspected cases of SSRI-induced neonatal withdrawal syndrome (including 13 cases of seizures) reported by November 2003, 64 were associated with paroxetine, 14 with fluoxetine, nine with sertraline, and seven with citalopram.
As a result, the investigators recommend that paroxetine not be used during pregnancy or, if it must be used, that it be given at the lowest effective dose. They also recommend that the use of other SSRIs during pregnancy be carefully monitored, and that physicians report any new cases of neonatal withdrawal syndrome promptly to appropriate authorities.
Cesarean delivery reduces mortality risk in preterm breech births
December 2nd 2024In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
No link found between prenatal cannabis use and childhood developmental delay
November 5th 2024In a recent study, offspring of women with cannabis use in early pregnancy confirmed by self-report or toxicology test were not at an increased risk of childhood early developmental delay up to the age of 5.5 years.
Read More
Prenatal cannabis use not linked to offspring ASD development
November 1st 2024In a recent study, adjustments for maternal characteristics mediated the association between maternal prenatal cannabis use and offspring autism spectrum disorder, indicating no statistically significant increase in risk.
Read More